19091394 Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. - Evidence Based Medicine on FHIR Implementation Guide v1.0.0-ballot

This page is part of the Evidence Based Medicine on FHIR Implementation Guide (v1.0.0-ballot: STU1 Ballot 1) based on FHIR (HL7® FHIR® Standard) v5.0.0. . For a full list of available versions, see the Directory of published versions

Example Citation: 19091394 Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.

Active as of 2023-12-17

Generated Narrative: Citation

Resource Citation "179627" Version "1" Updated "2023-11-26 22:35:25+0000"

StructureDefinition Work Group: cds

url: https://fevir.net/resources/Citation/179627

identifier: FEvIR Object Identifier: 179627, id: 19091394

version: 1.0.0-ballot

title: 19091394 Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.

status: active

date: 2023-12-17 16:55:23+0000

publisher: HL7 International / Clinical Decision Support

contact: HL7 International / Clinical Decision Support: http://www.hl7.org/Special/committees/dss

description: This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.

UseContexts

Code

Value[x]

FEvIR Platform Use (Details: http://hl7.org/fhir/citation-classification-type code fevir-platform-use = 'FEvIR Platform Use', stated as 'FEvIR Platform Use')

Medline Base (Citation Artifact Classifier#medline-base)

jurisdiction: World (m49.htm#001)

copyright: https://creativecommons.org/licenses/by-nc-sa/4.0/

approvalDate: 2009-02-05

lastReviewDate: 2022-03-30

author: Computable Publishing®: MEDLINE-to-FEvIR Converter:

classification
type: Citation Source (Citation Classification Type#citation-source)
classifier: MEDLINE ()

classification
type: MEDLINE Citation Owner (Citation Classification Type#medline-owner)
classifier: National Library of Medicine, Index Section (elements_descriptions.html#owner_value#NLM)

currentState: Medline Citation Status of Medline (Citation Status Type#medline-medline), PubMed PublicationStatus of ppublish (Citation Status Type#pubmed-publication-status-ppublish)

statusDate
activity: PubMed Pubstatus of Entrez (Citation Status Type#pubmed-pubstatus-entrez)
period: ?? --> 2008-12-19 09:00:00+0000

statusDate
activity: PubMed Pubstatus of Pubmed (Citation Status Type#pubmed-pubstatus-pubmed)
period: ?? --> 2008-12-19 09:00:00+0000

statusDate
activity: PubMed Pubstatus of Medline (Citation Status Type#pubmed-pubstatus-medline)
period: ?? --> 2009-02-06 09:00:00+0000

citedArtifact
identifier: id: 19091394, id: 10.1016/S0140-6736(08)61815-2, pii: S0140-6736(08)61815-2
relatedIdentifier: id: ISRCTN01534787
Titles
- Type Language Text
* Primary title (Title Type#primary) English (Tags for the Identification of Languages#en) Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.
Abstracts
- Text
* **BACKGROUND:** Several studies have shown the efficacy of endocrine therapy in combination with radiotherapy in high-risk prostate cancer. To assess the effect of radiotherapy, we did an open phase III study comparing endocrine therapy with and without local radiotherapy, followed by castration on progression. **METHODS:** This randomised trial included men from 47 centres in Norway, Sweden, and Denmark. Between February, 1996, and December, 2002, 875 patients with locally advanced prostate cancer (T3; 78%; PSA<70; N0; M0) were centrally randomly assigned by computer to endocrine treatment alone (3 months of total androgen blockade followed by continuous endocrine treatment using flutamide; 439 patients), or to the same endocrine treatment combined with radiotherapy (436 patients). The primary endpoint was prostate-cancer-specific survival, and analysis was by intention to treat. This study is registered as an international standard randomised controlled trial, number ISRCTN01534787. **FINDINGS:** After a median follow-up of 7.6 years, 79 men in the endocrine alone group and 37 men in the endocrine plus radiotherapy group had died of prostate cancer. The cumulative incidence at 10 years for prostate-cancer-specific mortality was 23.9% in the endocrine alone group and 11.9% in the endocrine plus radiotherapy group (difference 12.0%, 95% CI 4.9-19.1%), for a relative risk of 0.44 (0.30-0.66). At 10 years, the cumulative incidence for overall mortality was 39.4% in the endocrine alone group and 29.6% in the endocrine plus radiotherapy group (difference 9.8%, 0.8-18.8%), for a relative risk of 0.68 (0.52-0.89). Cumulative incidence at 10 years for PSA recurrence was substantially higher in men in the endocrine-alone group (74.7%vs 25.9%, p<0.0001; HR 0.16; 0.12-0.20). After 5 years, urinary, rectal, and sexual problems were slightly more frequent in the endocrine plus radiotherapy group. **INTERPRETATION:** In patients with locally advanced or high-risk local prostate cancer, addition of local radiotherapy to endocrine treatment halved the 10-year prostate-cancer-specific mortality, and substantially decreased overall mortality with fully acceptable risk of side-effects compared with endocrine treatment alone. In the light of these data, endocrine treatment plus radiotherapy should be the new standard.
relatesTo
type: correction-in
classifier: Published Erratum (#D016425)
citation: Lancet. 2009 Apr 4;373(9670):1174
relatesTo
type: comment-in
classifier: Comment (#D016420)
citation: Lancet. 2009 Jan 24;373(9660):274-6
Documents
- Url
* https://pubmed.ncbi.nlm.nih.gov/19091392/
resourceReference: id: 19091392
relatesTo
type: comment-in
classifier: Comment (#D016420)
citation: Nat Rev Urol. 2009 May;6(5):250-1
Documents
- Url
* https://pubmed.ncbi.nlm.nih.gov/19424171/
resourceReference: id: 19424171
relatesTo
type: comment-in
classifier: Comment (#D016420)
citation: Ann Intern Med. 2009 Jun 16;150(12):JC6-6
Documents
- Url
* https://pubmed.ncbi.nlm.nih.gov/19528551/
resourceReference: id: 19528551
relatesTo
type: comment-in
classifier: Comment (#D016420)
citation: Eur Urol. 2009 May;55(5):1240
Documents
- Url
* https://pubmed.ncbi.nlm.nih.gov/19650206/
resourceReference: id: 19650206
relatesTo
type: comment-in
classifier: Comment (#D016420)
citation: Eur Urol. 2009 May;55(5):1239-40
Documents
- Url
* https://pubmed.ncbi.nlm.nih.gov/19650231/
resourceReference: id: 19650231
publicationForm
PublishedIns
- Type Identifier Title PublisherLocation
* Periodical (Published In Type#D020492) Electronic ISSN Type: 1474-547X, ISOAbbreviation: Lancet, ISSN Linking: 0140-6736, Medline Title Abbreviation: Lancet, NLM Unique ID: 2985213R Lancet (London, England) England
citedMedium: Internet (Cited Medium#internet)
volume: 373
issue: 9660
articleDate: 2009-01-24
publicationDateText: 2009-Jan-24
language: English (Tags for the Identification of Languages#en)
pageString: 301-8
publicationForm
citedMedium: Internet without issue (Cited Medium#internet-without-issue)
articleDate: 2008-12-16
webLocation
classifier: Abstract (Artifact Url Classifier#abstract)
url: https://pubmed.ncbi.nlm.nih.gov/19091394/
webLocation
classifier: DOI Based (Artifact Url Classifier#doi-based)
url: https://doi.org/10.1016/S0140-6736(08)61815-2
classification
type: Publishing Model (Cited Artifact Classification Type#publishing-model)
classifier: Print Electronic (Citation Artifact Classifier#Print-Electronic)
classification
type: Chemical (Cited Artifact Classification Type#chemical)
classifier: Androgen Antagonists (#D000726), Flutamide (chemical-substances#76W6J0943E; #D005485)
classification
type: MeSH Heading (Cited Artifact Classification Type#mesh-heading)
artifactAssessment:

artifact: #
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Aged (#D000368)
freeToShare: true
Components
- Type Classifier
* qualifier () is not a major topic ()
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Androgen Antagonists (#D000726)
freeToShare: true
component
type: qualifier ()
classifier: is not a major topic ()
component
type: qualifier ()
classifier: therapeutic use (#Q000627)
component
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Combined Modality Therapy (#D003131)
freeToShare: true
Components
- Type Classifier
* qualifier () is not a major topic ()
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Flutamide (#D005485)
freeToShare: true
component
type: qualifier ()
classifier: is not a major topic ()
component
type: qualifier ()
classifier: therapeutic use (#Q000627)
component
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Humans (#D006801)
freeToShare: true
Components
- Type Classifier
* qualifier () is not a major topic ()
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Male (#D008297)
freeToShare: true
Components
- Type Classifier
* qualifier () is not a major topic ()
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Prostatectomy (#D011468)
freeToShare: true
Components
- Type Classifier
* qualifier () is not a major topic ()
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Prostatic Neoplasms (#D011471)
freeToShare: true
component
type: qualifier ()
classifier: is not a major topic ()
component
type: qualifier ()
classifier: drug therapy (#Q000188)
component
component
type: qualifier ()
classifier: mortality (#Q000401)
component
component
type: qualifier ()
classifier: radiotherapy (#Q000532)
component
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Severity of Illness Index (#D012720)
freeToShare: true
Components
- Type Classifier
* qualifier () is not a major topic ()
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Survival Analysis (#D016019)
freeToShare: true
Components
- Type Classifier
* qualifier () is not a major topic ()
classification
type: Publication Type (Cited Artifact Classification Type#publication-type)
classifier: Clinical Trial, Phase III (#D017428), Journal Article (#D016428), Multicenter Study (#D016448), Randomized Controlled Trial (#D016449), Research Support, Non-U.S. Gov't (#D013485)
classification
type: Knowledge Artifact Type (Cited Artifact Classification Type#knowledge-artifact-type)
classifier: Journal Article (Citation Artifact Classifier#D016428)
artifactAssessment: : Classifier added by Computable Publishing LLC
classification
type: Citation Subset (Cited Artifact Classification Type#citation-subset)
classifier: IM (elements_descriptions.html#citationsubset#IM)
contributorship
complete: true
entry
contributor:

name: Anders Widmark
forenameInitials: A
affiliation: : Department of Radiation Sciences, Oncology, Umeå University, Umeå, Sweden.
entry
contributor:

name: Olbjørn Klepp
forenameInitials: O
entry
contributor:

name: Arne Solberg
forenameInitials: A
entry
contributor:

name: Jan-Erik Damber
forenameInitials: JE
entry
contributor:

name: Anders Angelsen
forenameInitials: A
entry
contributor:

name: Per Fransson
forenameInitials: P
entry
contributor:

name: Jo-Asmund Lund
forenameInitials: JA
entry
contributor:

name: Ilker Tasdemir
forenameInitials: I
entry
contributor:

name: Morten Hoyer
forenameInitials: M
entry
contributor:

name: Fredrik Wiklund
forenameInitials: F
entry
contributor:

name: Sophie D Fosså
forenameInitials: SD
entry
contributor:

name: Scandinavian Prostate Cancer Group Study 7
entry
contributor:

name: Swedish Association for Urological Oncology 3

Generated Narrative: Practitioner #author0
name: Anders Widmark

Generated Narrative: Practitioner #author1
name: Olbjørn Klepp

Generated Narrative: Practitioner #author2
name: Arne Solberg

Generated Narrative: Practitioner #author3
name: Jan-Erik Damber

Generated Narrative: Practitioner #author4
name: Anders Angelsen

Generated Narrative: Practitioner #author5
name: Per Fransson

Generated Narrative: Practitioner #author6
name: Jo-Asmund Lund

Generated Narrative: Practitioner #author7
name: Ilker Tasdemir

Generated Narrative: Practitioner #author8
name: Morten Hoyer

Generated Narrative: Practitioner #author9
name: Fredrik Wiklund

Generated Narrative: Practitioner #author10
name: Sophie D Fosså

Generated Narrative: Organization #author11
name: Scandinavian Prostate Cancer Group Study 7

Generated Narrative: Organization #author12
name: Swedish Association for Urological Oncology 3

Generated Narrative: ArtifactAssessment #meshHeading0
artifact: #
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Aged (#D000368)
freeToShare: true
Components
- Type Classifier
* qualifier () is not a major topic ()
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Androgen Antagonists (#D000726)
freeToShare: true
component
type: qualifier ()
classifier: is not a major topic ()
component
type: qualifier ()
classifier: therapeutic use (#Q000627)
component
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Combined Modality Therapy (#D003131)
freeToShare: true
Components
- Type Classifier
* qualifier () is not a major topic ()
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Flutamide (#D005485)
freeToShare: true
component
type: qualifier ()
classifier: is not a major topic ()
component
type: qualifier ()
classifier: therapeutic use (#Q000627)
component
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Humans (#D006801)
freeToShare: true
Components
- Type Classifier
* qualifier () is not a major topic ()
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Male (#D008297)
freeToShare: true
Components
- Type Classifier
* qualifier () is not a major topic ()
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Prostatectomy (#D011468)
freeToShare: true
Components
- Type Classifier
* qualifier () is not a major topic ()
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Prostatic Neoplasms (#D011471)
freeToShare: true
component
type: qualifier ()
classifier: is not a major topic ()
component
type: qualifier ()
classifier: drug therapy (#Q000188)
component
component
type: qualifier ()
classifier: mortality (#Q000401)
component
component
type: qualifier ()
classifier: radiotherapy (#Q000532)
component
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Severity of Illness Index (#D012720)
freeToShare: true
Components
- Type Classifier
* qualifier () is not a major topic ()
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Survival Analysis (#D016019)
freeToShare: true
Components
- Type Classifier
* qualifier () is not a major topic ()